• About PAH

• About Ventavis

•      Indications

•      Clinical Trials

•           Clinical Improvement

•           Improved Exercise
            Capacity

•           Functional Class
            Improvement

•           Improved
            Hemodynamics

•      Safety Profile

•      Dosage & Administration

•      Ventavis AirTime

•      FAQs

•      Ventavis Support

• About the I-neb AAD
  System

• Services for Your Patients

• Resources

• Prescribing Information

• For Patients and
  Caregivers

Efficacy

Ventavis^® (iloprost) Inhalation Solution is a synthetic analogue of prostacyclin PGI_2.¹ It dilates system and pulmonary arterial vascular beds. It also affects platelet aggregation, although the relevance of this effect to the treatment of pulmonary arterial hypertension is unknown.¹

In clinical studies, Ventavis has been shown to help with the following^1,2:

• Significant improvement in a composite endpoint of patient improvement—improvement in functional class, 10% or greater increase in individual walk distance, and lack of clinical deterioration or death (p=0.0033)^1,2*
• Significant improvement in exercise capacity (p<0.01)^1,2*
• Significant improvement in NYHA functional class (p=0.03)^1,2

Read more about How Ventavis Helps Patients:

• Clinical Improvement
• Improved Exercise Capacity
• Functional Class Improvement
• Improved Hemodynamics
• Safety Profile

1. Ventavis (iloprost) Full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2009.
2. Olschewski H, Simonneau G, Galie N et al, for the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.

For more information about
Ventavis, please call
1-866-ACTELION (1-866-228-3546).